NOV120101 Phase 2 Study in NSCLC Patients With Aquired Resistance to 1st Generation EGFR Tyrosine Kinase Inhibitors
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this open-label, single-arm, multi-center phase II trial is to evaluate the
efficacy and safety of novel pan-HER inhibitor, NOV120101 (Poziotinib), as a 2nd line
monotherapy agent in lung adenocarcinoma patients with acquired resistance to prior EGFR
tyrosine kinase inhibitors (TKIs).